226 related articles for article (PubMed ID: 32584141)
21. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic benefit of ivacaftor in late cystic fibrosis caused by homozygous IVS8-5T CFTR polymorphism.
Magne F; Durupt S; Nove-Josserand R; Bey-Omar F; Laoust L; Cottin V; Durieu I; Reynaud Q
J Cyst Fibros; 2017 Jan; 16(1):89-90. PubMed ID: 27810230
[No Abstract] [Full Text] [Related]
23. Effectivenesss of ivacaftor in severe cystic fibrosis patients and non-G551D gating mutations.
Salvatore D; Carnovale V; Iacotucci P; Braggion C; Castellani C; Cimino G; Colangelo C; Francalanci M; Leonetti G; Lucidi V; Manca A; Vitullo P; Ferrara N
Pediatr Pulmonol; 2019 Sep; 54(9):1398-1403. PubMed ID: 31237430
[TBL] [Abstract][Full Text] [Related]
24. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
[TBL] [Abstract][Full Text] [Related]
25. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
McPhail GL; Clancy JP
Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
[TBL] [Abstract][Full Text] [Related]
26. Ivacaftor as salvage therapy in a patient with cystic fibrosis genotype F508del/R117H/IVS8-5T.
Carter S; Kelly S; Caples E; Grogan B; Doyle J; Gallagher CG; McKone EF
J Cyst Fibros; 2015 Jul; 14(4):e4-5. PubMed ID: 25698453
[TBL] [Abstract][Full Text] [Related]
27. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for ivacaftor therapy in the context of CFTR genotype.
Clancy JP; Johnson SG; Yee SW; McDonagh EM; Caudle KE; Klein TE; Cannavo M; Giacomini KM;
Clin Pharmacol Ther; 2014 Jun; 95(6):592-7. PubMed ID: 24598717
[TBL] [Abstract][Full Text] [Related]
28. Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis.
Derichs N
Eur Respir Rev; 2013 Mar; 22(127):58-65. PubMed ID: 23457166
[TBL] [Abstract][Full Text] [Related]
29. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.
Davies J; Sheridan H; Bell N; Cunningham S; Davis SD; Elborn JS; Milla CE; Starner TD; Weiner DJ; Lee PS; Ratjen F
Lancet Respir Med; 2013 Oct; 1(8):630-638. PubMed ID: 24461666
[TBL] [Abstract][Full Text] [Related]
30. Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor.
Graeber SY; Hug MJ; Sommerburg O; Hirtz S; Hentschel J; Heinzmann A; Dopfer C; Schulz A; Mainz JG; Tümmler B; Mall MA
Am J Respir Crit Care Med; 2015 Nov; 192(10):1252-5. PubMed ID: 26568242
[No Abstract] [Full Text] [Related]
31. Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis.
O'Reilly R; Elphick HE
Drug Des Devel Ther; 2013; 7():929-37. PubMed ID: 24039402
[TBL] [Abstract][Full Text] [Related]
32. Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients.
Moheet A; Beisang D; Zhang L; Sagel SD; VanDalfsen JM; Heltshe SL; Frederick C; Mann M; Antos N; Billings J; Rowe SM; Moran A;
J Cyst Fibros; 2021 Mar; 20(2):333-338. PubMed ID: 32917547
[TBL] [Abstract][Full Text] [Related]
33. Ivacaftor-induced sweat chloride reductions correlate with increases in airway surface liquid pH in cystic fibrosis.
Abou Alaiwa MH; Launspach JL; Grogan B; Carter S; Zabner J; Stoltz DA; Singh PK; McKone EF; Welsh MJ
JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089726
[TBL] [Abstract][Full Text] [Related]
34. Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation.
Sermet-Gaudelus I
Eur Respir Rev; 2013 Mar; 22(127):66-71. PubMed ID: 23457167
[TBL] [Abstract][Full Text] [Related]
35. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.
Rowe SM; Heltshe SL; Gonska T; Donaldson SH; Borowitz D; Gelfond D; Sagel SD; Khan U; Mayer-Hamblett N; Van Dalfsen JM; Joseloff E; Ramsey BW;
Am J Respir Crit Care Med; 2014 Jul; 190(2):175-84. PubMed ID: 24927234
[TBL] [Abstract][Full Text] [Related]
36. SLC26A9 SNP rs7512462 is not associated with lung disease severity or lung function response to ivacaftor in cystic fibrosis patients with G551D-CFTR.
Eastman AC; Pace RG; Dang H; Aksit MA; Vecchio-Pagán B; Lam AN; O'Neal WK; Blackman SM; Knowles MR; Cutting GR
J Cyst Fibros; 2021 Sep; 20(5):851-856. PubMed ID: 33674211
[TBL] [Abstract][Full Text] [Related]
37. CORK Study in Cystic Fibrosis: Sustained Improvements in Ultra-Low-Dose Chest CT Scores After CFTR Modulation With Ivacaftor.
Ronan NJ; Einarsson GG; Twomey M; Mooney D; Mullane D; NiChroinin M; O'Callaghan G; Shanahan F; Murphy DM; O'Connor OJ; Shortt CA; Tunney MM; Eustace JA; Maher MM; Elborn JS; Plant BJ
Chest; 2018 Feb; 153(2):395-403. PubMed ID: 29037527
[TBL] [Abstract][Full Text] [Related]
38. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
Kuk K; Taylor-Cousar JL
Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
[TBL] [Abstract][Full Text] [Related]
39. Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation.
Harris JK; Wagner BD; Zemanick ET; Robertson CE; Stevens MJ; Heltshe SL; Rowe SM; Sagel SD
Ann Am Thorac Soc; 2020 Feb; 17(2):212-220. PubMed ID: 31604026
[No Abstract] [Full Text] [Related]
40. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation.
Davies JC; Wainwright CE; Canny GJ; Chilvers MA; Howenstine MS; Munck A; Mainz JG; Rodriguez S; Li H; Yen K; Ordoñez CL; Ahrens R;
Am J Respir Crit Care Med; 2013 Jun; 187(11):1219-25. PubMed ID: 23590265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]